Alpha 2.0
Login Register
» Authors » Paul T Scott

Paul T Scott

Explore the profile of Paul T Scott including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 91
Citations 1198
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Public Health
Top 10 Co-Authors
Nelson L Michael
Shilpa Hakre
Sheila A Peel
Kayvon Modjarrad
Catherine S Todd
Jason F Okulicz
Linda L Jagodzinski
Sodsai Tovanabutra
Christian T Bautista
Steffanie A Strathdee
Published In
PLoS One
Mil Med
J Acquir Immune Defic Syndr
AIDS Res Hum Retroviruses
Transfusion
Affiliations
Soon will be listed here.
Recent Articles
1.
Safety and immunogenicity of a next-generation live-attenuated yellow fever vaccine produced in a Vero cell line in the USA: a phase 1 randomised, observer-blind, active-controlled, dose-ranging clinical trial
Modjarrad K, Scott P, McCauley M, Ober-Shepherd B, Sondergaard E, Amare M, et al.
Lancet Infect Dis . 2024 Aug; 24(12):1393-1402. PMID: 39153488
Background: Recent outbreaks between 2015-17 and production delays have led to a yellow fever vaccine shortage. Therefore, there is an urgent need for new yellow fever vaccines with improved production...
2.
Prevalence of Infection and Macrolide and Fluoroquinolone Resistance Mutations Among US Air Force Service Members With HIV, 2016-2020
Hakre S, Sanders-Buell E, Casimier R, OSullivan A, Peel S, Tovanabutra S, et al.
Open Forum Infect Dis . 2024 Jul; 11(7):ofae407. PMID: 39077051
Background: (MG) infection is a public health concern due to antimicrobial resistance (AMR). Data are limited on repeat MG infection and AMR among US Air Force service members with HIV....
3.
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial
Ober Shepherd B, Scott P, Hutter J, Lee C, McCauley M, Guzman I, et al.
Lancet Microbe . 2024 May; 5(6):e581-e593. PMID: 38761816
Background: A self-assembling SARS-CoV-2 WA-1 recombinant spike ferritin nanoparticle (SpFN) vaccine co-formulated with Army Liposomal Formulation (ALFQ) adjuvant containing monophosphoryl lipid A and QS-21 (SpFN/ALFQ) has shown protective efficacy in...
4.
Clinical, molecular, and drug resistance epidemiology of HIV in Jordan, 2019-2021: A national study
Bakri F, Mukattash H, Esmeiran H, Schluck G, Storme C, Broach E, et al.
Int J Infect Dis . 2024 May; 145:107079. PMID: 38697607
Background: Limited epidemiologic studies have been conducted in Jordan describing the HIV epidemic. This study aimed to address this gap to inform HIV prevention and control. Methods: A nationally-representative cross-sectional...
5.
Risk of sexually transmitted infections among U.S. military service members in the setting of HIV pre-exposure prophylaxis use
Blaylock J, Ewers E, Bianchi E, King D, Casimier R, Erazo H, et al.
PLoS One . 2023 Dec; 18(12):e0296054. PMID: 38153953
Background: The evidence for an increased incidence of sexually transmitted infections (STIs) among patients utilizing HIV pre-exposure prophylaxis (PrEP) has been inconsistent. We assessed the risk of incident STI while...
6.
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial
Mwesigwa B, Houser K, Hofstetter A, Ortega-Villa A, Naluyima P, Kiweewa F, et al.
Lancet Infect Dis . 2023 Aug; 23(12):1408-1417. PMID: 37544326
Background: Sudan Ebola virus can cause severe viral disease, with an average case fatality rate of 54%. A recent outbreak of Sudan Ebola virus in Uganda caused 55 deaths among...
7.
Analytical validation of quantitative SARS-CoV-2 subgenomic and viral load laboratory developed tests conducted on the Panther Fusion® (Hologic) with preliminary application to clinical samples
Lakhal-Naouar I, Hack H, Moradel E, Jarra A, Grove H, Ismael R, et al.
PLoS One . 2023 Jun; 18(6):e0287576. PMID: 37384714
Objective: Validate the performance characteristics of two analyte specific, laboratory developed tests (LDTs) for the quantification of SARS-CoV-2 subgenomic RNA (sgRNA) and viral load on the Hologic Panther Fusion® using...
8.
Community incidence patterns drive the risk of SARS-CoV-2 outbreaks and alter intervention impacts in a high-risk institutional setting
Moore S, Espana G, Perkins T, Guido R, Jucaban J, Hall T, et al.
Epidemics . 2023 Jun; 43:100691. PMID: 37267710
Optimization of control measures for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in high-risk institutional settings (e.g., prisons, nursing homes, or military bases) depends on how transmission dynamics in the...
9.
Transmission of SARS-CoV-2 among recruits in a US Army training environment: a brief report
Hakre S, Maljkovic-Berry I, Hang J, Conte M, Pollio A, Fung C, et al.
J Public Health (Oxf) . 2023 May; 45(3):748-752. PMID: 37132356
Background: In 2020, preventive measures were implemented to mitigate the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among 600-700 recruits arriving weekly at a basic combat training (BCT)...
10.
Investigation of an outbreak of COVID-19 among U.S. military personnel and beneficiaries stationed in the Republic of Korea, June-July 2021
Hakre S, Lam E, Maljkovic-Berry I, Hang J, Pow Sang L, Bianchi E, et al.
PLOS Glob Public Health . 2023 Mar; 2(5):e0000236. PMID: 36962352
On 28 May 2021, leisure travel restrictions in place to control coronavirus disease 2019 (COVID-19) were eased among vaccinated U.S. military personnel and beneficiaries stationed in South Korea (USFK) allowing...